We have located links that may give you full text access.
Growth differentiation factor-15 (GDF-15) predicts major bleeding, major adverse cardiac events, and mortality in patients with end-stage kidney disease on hemodialysis: findings from the VIVALDI study.
Nephrology, Dialysis, Transplantation 2022 December 7
BACKGROUND: Patients with end-stage kidney disease (ESKD) are at high risk of cardiovascular events and bleeding. Optimizing risk assessment of ESKD patients regarding risk of thromboembolism and bleeding complications in comorbid conditions, including atrial fibrillation and coronary heart disease, is challenging. To improve risk prediction we investigated growth differentiation factor-15 (GDF-15), a promising cardiovascular biomarker, and its relation to adverse outcomes.
METHODS: In this prospective multicenter population-based cohort study, GDF-15 was measured in 594 ESKD patients on hemodialysis (median age: 66 years, 38% women), who were followed-up for in median 3.5 years. The association of GDF-15 with major bleeding, arterial thromboembolism, major adverse cardiac events (MACE), and death was analyzed within a competing risk framework. Further, we evaluated the additive predictive value of GDF-15 to cardiovascular and death risk assessment.
RESULTS: GDF-15 levels were 5475ng/L in median (25th-75th percentile: 3964-7533) and independently associated with major bleeding (subdistribution hazard ratio [SHR] 1.31 per double increase, 95%CI 1.00-1.71), MACE (SHR 1.47, 1.11-1.94), and all-cause mortality (SHR 1.58, 1.28-1.95) but not arterial thromboembolism (SHR 0.91, 95%CI 0.61-1.36). Addition of GDF-15 to the HAS-BLED score significantly improved discrimination and calibration for predicting major bleeding (C-statistics increased from 0.61 (95%CI 0.52-0.70) to 0.68 (95%CI 0.61-0.78)). Furthermore, we established an additive predictive value of GDF-15 beyond current risk models for predicting MACE and death.
CONCLUSION: GDF-15 predicts risk of major bleeding, cardiovascular events, and death in ESKD patients on hemodialysis and might be a valuable marker to guide treatment decisions in this challenging patient population.
METHODS: In this prospective multicenter population-based cohort study, GDF-15 was measured in 594 ESKD patients on hemodialysis (median age: 66 years, 38% women), who were followed-up for in median 3.5 years. The association of GDF-15 with major bleeding, arterial thromboembolism, major adverse cardiac events (MACE), and death was analyzed within a competing risk framework. Further, we evaluated the additive predictive value of GDF-15 to cardiovascular and death risk assessment.
RESULTS: GDF-15 levels were 5475ng/L in median (25th-75th percentile: 3964-7533) and independently associated with major bleeding (subdistribution hazard ratio [SHR] 1.31 per double increase, 95%CI 1.00-1.71), MACE (SHR 1.47, 1.11-1.94), and all-cause mortality (SHR 1.58, 1.28-1.95) but not arterial thromboembolism (SHR 0.91, 95%CI 0.61-1.36). Addition of GDF-15 to the HAS-BLED score significantly improved discrimination and calibration for predicting major bleeding (C-statistics increased from 0.61 (95%CI 0.52-0.70) to 0.68 (95%CI 0.61-0.78)). Furthermore, we established an additive predictive value of GDF-15 beyond current risk models for predicting MACE and death.
CONCLUSION: GDF-15 predicts risk of major bleeding, cardiovascular events, and death in ESKD patients on hemodialysis and might be a valuable marker to guide treatment decisions in this challenging patient population.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
Intravenous infusion of dexmedetomidine during the surgery to prevent postoperative delirium and postoperative cognitive dysfunction undergoing non-cardiac surgery: a meta-analysis of randomized controlled trials.European Journal of Medical Research 2024 April 19
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Systemic lupus erythematosus.Lancet 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app